ReviewHaematologica2018
Preclinical human models and emerging therapeutics for advanced systemic mastocytosis.
Review in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Article
- Primary sclerosing cholangitis displays distinct colonic mucosa topography yet a shared mast cell state with ulcerative colitis.Nature communications · 2026Article
- Enhanced PIEZO1 expression in mast cells of mastocytosis skin lesions: Relevance to Darier's sign.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Impact ofJournal of inflammation research · 2025Article
- The Forgotten Innate Immune Cells: Unraveling Their Prospective Interactions with Nanomaterials.International journal of nanomedicine · 2025Review
- Mutational Landscape ofVeterinary sciences · 2024Article
- Metformin: A potential adjunct for treatment of systemic mastocytosis.The journal of allergy and clinical immunology. Global · 2024Article
- Drug delivery targets and strategies to address mast cell diseases.Expert opinion on drug delivery · 2023Review
- CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.Frontiers in immunology · 2023Article
- Article
- KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6.Haematologica · 2020Article
- Description and Characterization of a Novel Human Mast Cell Line for Scientific Study.International journal of molecular sciences · 2019Article
- Recent advances in the understanding and therapeutic management of mastocytosis.F1000Research · 2019Review
- Mastocytosis: One Word for Different Diseases.Oncology and therapy · 2018Review
- Educational Case: Systemic Mastocytosis with an Associated Hematological Neoplasm.Academic pathologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 4 countries.
Funding
Abstract
Mastocytosis is a term used to denote a group of rare diseases characterized by an abnormal accumulation of neoplastic mast cells in various tissues and organs. In most patients with systemic mastocytosis, the neoplastic cells carry activating mutations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.